研发管线 · 10 个在研/已上市资产 · BCMA CAR-T 商业化 + 体内 in-vivo CAR-T 平台
IASO Bio is a commercial-stage ATMP (advanced therapy medicinal products) company founded 2017, focused on cell therapies and biologics for hematologic malignancies and autoimmune disease. Its core commercial product is the fully-human BCMA-targeted autologous CAR-T equecabtagene autoleucel (eque-cel, brand 福可苏®/Fucaso®, internal code CT103A), approved in China (NMPA, Jun 2023) for r/r MM after >=3 prior lines and now expanding to earlier lines and autoimmune indications. The company runs an integrated platform spanning a >240-billion fully-human antibody library, high-throughput CAR-T screening, an in-vivo CAR-T platform (engineered lentiviral vectors + T-cell-specific promoters delivering CAR genes directly inside the patient, no ex-vivo manufacturing), and advanced CMC/manufacturing. The portfolio comprises 1 commercialized product plus 9 pipeline candidates: 3 ex-vivo (autologous) CAR-T, 5 in-vivo CAR-T, and 1 antibody.
管线相位图 Pipeline
按最advanced适应症相位填充；点击展开各适应症 · 颜色＝modality（体内平台为核心）
催化剂日历 × 现金跑道
前瞻申报/读出 + 近期里程碑，叠加现金跑道覆盖范围（IR 核心：现金能否撑到下一个价值拐点）
前瞻催化剂 Catalysts
现金跑道覆盖至 ≈ 2029 年中按当前烧钱速度，近 1–2 年内的注册申报与数据读出催化剂落在现金跑道覆盖范围内。
近期里程碑 Recent
数据口径：PRIMARY SOURCE = 招股书.pdf (HK prospectus, Traditional Chinese) pipeline table + 'Recent developments' (近期发展) + program-detail sections; this is the most authoritative and current pipeline source. Fully…
管线/临床数据来源：HK 招股书 + Cure deck（公开 IR 材料，as of Latest Practicable Date in prospectus (FY data cutoff 2025-06-30; pipeline status reflects events through 2025-10)）。